Patent intelligence · US
US 9133162
Substituted quinoline compounds and methods of use
Substituted quinoline compounds and methods of use
Patent details — US 9133162
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 15, 2015
- Expiration
- Sep 10, 2035
- Applicant
- SUNSHINE LAKE PHARMA CO., LTD.
- Claims
- 8
- CPC classes
- A61K, A61K31/436, A61K31/4709, A61K38/21
Quick answer
US 9133162 (Substituted quinoline compounds and methods of use) is held by SUNSHINE LAKE PHARMA CO., LTD.. Status: granted. Granted Sep 15, 2015. Expires Sep 10, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SUNSHINE LAKE PHARMA CO., LTD.
- Grant date
- Expiration
- Claims
- 8
- CPC classes
- A61K, A61K31/436, A61K31/4709, A61K38/21, A61K45/06, A61P
More from SUNSHINE LAKE PHARMA CO., LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12428432
Thienopyrimidine derivatives having stereo configurations and use thereof in medicine
granted -
US 12428389
Diarylamide compound and application thereof
granted -
US 12384853
Anti-HER2/PD1 bispecific antibody
granted -
US 12324812
Glucopyranosyl derivatives and their uses
granted -
US 12319748
Antibody binding to human HER2 and preparation method and use thereof
granted -
US 12312348
RET inhibitors, pharmaceutical compositions and uses thereof
granted -
US 12269886
Tetravalent bispecific antibody against PD-1 and PD-L1
granted -
US 12258317
Isoquinolinone compound for inhibiting ssao/vap-1, and use thereof
granted
Frequently asked questions
What is US patent 9133162?
US 9133162 (Substituted quinoline compounds and methods of use) is held by SUNSHINE LAKE PHARMA CO., LTD.. Status: granted. Granted Sep 15, 2015. Expires Sep 10, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9133162?
SUNSHINE LAKE PHARMA CO., LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 121 pharmaceutical patents for this assignee.
When does US 9133162 expire?
Our index shows an expiration date of Sep 10, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.